Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/5681
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde Wit, R.-
dc.contributor.authorSYLVESTER, Richard-
dc.contributor.authorTsitsa, C.-
dc.contributor.authorde Mulder, P.H.M.-
dc.contributor.authorSleyfer, D.T.-
dc.contributor.authorten Bokkel Huinink, W.W.-
dc.contributor.authorKaye, S.B.-
dc.contributor.authorvan Oosterom, A.T.-
dc.contributor.authorBoven, E.-
dc.contributor.authorStoter, G.-
dc.date.accessioned2007-12-20T16:01:02Z-
dc.date.available2007-12-20T16:01:02Z-
dc.date.issued1997-
dc.identifier.citationBritish journal of cancer, 75. p. 432-435-
dc.identifier.urihttp://hdl.handle.net/1942/5681-
dc.titleTumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminatomous testicular cancer-
dc.typeJournal Contribution-
dc.identifier.epage435-
dc.identifier.spage432-
dc.identifier.volume75-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcat-
item.accessRightsClosed Access-
item.fullcitationde Wit, R.; SYLVESTER, Richard; Tsitsa, C.; de Mulder, P.H.M.; Sleyfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; van Oosterom, A.T.; Boven, E. & Stoter, G. (1997) Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminatomous testicular cancer. In: British journal of cancer, 75. p. 432-435.-
item.fulltextNo Fulltext-
item.contributorde Wit, R.-
item.contributorSYLVESTER, Richard-
item.contributorTsitsa, C.-
item.contributorde Mulder, P.H.M.-
item.contributorSleyfer, D.T.-
item.contributorten Bokkel Huinink, W.W.-
item.contributorKaye, S.B.-
item.contributorvan Oosterom, A.T.-
item.contributorBoven, E.-
item.contributorStoter, G.-
Appears in Collections:Research publications
Show simple item record

Page view(s)

32
checked on Nov 7, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.